KAHF Biotech, Inc.

Building a target-centric therapeutic ecosystem for next-generation cancer treatment

https://wefunder.com/kahf.biotech.inc

Total raised on Wefunder: 62000

Total investors: 10

Quick facts

  • A novel target in PDAC with limited prior characterization and promising preclinical validation
  • Dual therapeutic strategy: blocks metastasis early and kills tumors in late-stage disease
  • Capital-efficient plan: lead antibody development achievable at low cost
  • Platform approach expandable to multiple solid tumors expressing the same receptor
  • Lead antibody can be expanded into ADC, CAR-T cells, and Degrader Antibody conjugates (DACs)
  • Founded by PhD cancer scientist with deep expertise in cancer therapeutic development platforms

Team profiles

Featured investor profiles

Invest in KAHF Biotech, Inc.

Building a target-centric therapeutic ecosystem for next-generation cancer treatment

FIRST GOAL HIT (You can still invest)

$65,000

raised from 11 investors
INVESTMENT TERMS
Future Equity
$10M valuation cap 20% discount
$10K

Highlights

1
A novel target in PDAC with limited prior characterization and promising preclinical validation
2
Dual therapeutic strategy: blocks metastasis early and kills tumors in late-stage disease
3
Capital-efficient plan: lead antibody development achievable at low cost
4
Platform approach expandable to multiple solid tumors expressing the same receptor

Related company links

Featured Investor

Team

Advancing a target-centric therapeutic ecosystem for next-generation cancer treatment across diverse tumor types.

Pleased to share that KAHF Biotech, Inc. has announced the filing of patent-pending technology supporting its next-generation therapeutic platform focused on the development of novel cancer therapeutics and diagnostics. The company’s platform-based intellectual property portfolio encompasses a broad range of therapeutic and diagnostic modalities designed to target critical drivers of tumor progression, metastatic disease, and treatment resistance across solid and hematological tumors.

The portfolio includes first-in-class approaches spanning antibody-drug conjugates (ADCs), T cell engager, Monoclonal Antibody, CAR-T cell therapies, antibody-oligonucleotide conjugates (AOCs), degrader-antibody conjugates (DACs), DsiRNA-based therapeutics, targeted biologics, companion diagnostics, and additional precision oncology applications. The platform is designed to support the development of multiple therapeutic strategies across diverse cancer indications while enabling future expansion into combination therapies and translational diagnostic technologies.

This patent-pending platform represents an important milestone in KAHF Biotech’s mission to advance innovative therapeutic approaches for patients with aggressive cancers. We believe the breadth of this platform provides significant opportunities for future therapeutic development, strategic partnerships, and translational research.

KAHF Biotech continues to advance preclinical research and platform development efforts focused on translating emerging scientific discoveries into targeted oncology therapeutics.

“Our vision is to revolutionize cancer treatment particularly metastatic disease by developing impactful, effective, and affordable therapies that are accessible to cancer patients worldwide. We aim to overcome the current challenges of metastatic disease and ensure that groundbreaking treatments reach those who need them most, no matter where they are.”

Muhammad Sadeqi Nezhad, Ph.D.

Founder & Chief Executive Officer

KAHF Biotech, Inc.

Overview